SPK1/S1P axis confers gastrointestinal stromal tumors (GISTs) resistance of imatinib.

ABSTRACT:

Background

Imatinib mesylate (IM) is highly effective in the treatment of gastrointestinal stromal tumors (GISTs). However, the most of GISTs patients develop secondary drug resistance after 1-3 years of IM treatment. The aim of this study was to explore the IM-resistance mechanism via the multi-scope combined with plasma concentration of IM, genetic polymorphisms and plasma sensitive metabolites.

Methods

This study included a total of 40 GISTs patients who had been regularly treated and not treated with IM. The plasma samples were divided into three experiments, containing therapeutic drug monitoring (TDM), OCT1 genetic polymorphisms and non-targeted metabolomics. According to the data of above three experiments, the IM-resistant cell line, GIST-T1/IMR cells, was constructe

SUBMITTER: Chen Y 

PROVIDER: S-EPMC9398498 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature